Please login to the form below

Not currently logged in
Email:
Password:

Hanmi

This page shows the latest Hanmi news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

In 2015, J&J and Hanmi entered an alliance to develop efinopegdutide to treat diabetes and obesity, with Hanmi receiving an upfront payment of $105m for the drug. ... The deal with Hanmi builds on Merck’s existing NASH pipeline, which includes a

Latest news

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Hanmi (SK) / Jul 15. Boehringer Ing. (DE). Olmuntinib / Lung cancer.

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch November 2015 Deal Watch November 2015

    $900m of which two were with the same company, Hanmi Pharmaceutical, a Korean public company. ... Option to co-develop/co-commercialise EU/US. 1, 560. Hanmi Pharmaceutical. Janssen Pharmaceuticals. Licence.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    750. Hanmi / Eli Lilly. Licence and collaboration. Phase 1 BTK inhibitor for treatment of lupus.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Lilly's expedition to the Far East also generated another deal this month, the licence of a phase 1 BTK inhibitor from the Korean company Hanmi for up to $690m.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....